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Summary
Objectives: To determine the impact of erythema nodosum leprosum (ENL) on health-
related quality of life (HRQoL) of persons affected by leprosy compared to individuals
without ENL using theMedical Outcomes Study: 36-Item Short Form Survey (SF-36).
Methods: Individuals with a diagnosis of leprosy completed the Bengali version of the
SF-36. The responses to the items of the surveys were coded, summed and transformed
into a score for each of the eight domains. A lower score reflects a worse HRQoL.
Results: 290 individuals with a median age of 32 years (Range 14–82) participated.
Individuals with ENL and those with isolated neuritis had significantly lower mean
scores in all domains compared with individuals without reaction or neuritis except
the domain of physical functioning in those with ENL.
Conclusions: This study demonstrates an association of reduced HRQoL with ENL
compared to individuals without reaction or neuritis.
Keywords: Erythema nodosum leprosum, health related quality of life, leprosy, nerve
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Introduction
Leprosy is a disabling disease that may lead to stigma and discrimination. The World Health
Organization (WHO) multi-drug therapy (MDT) has been successful in treating the infection.
However individuals still experience disability secondary to nerve function impairment. Over
200,000 new cases of leprosy were reported to WHO in 2017 and 63% of these cases were
from India.2 In India 4.6% of individuals had Grade 2 disability at the time of diagnosis.3
Leprosy patients continue to develop disability during or after MDT.4 Disability is associated
with worse health related quality of life (HRQoL).5
HRQoL is defined as a person’s perception of his or her physical and mental health
and covers broad domains including physical, psychological, economic, spiritual and social
wellbeing.6 HRQoL in leprosy is hampered in the areas of prejudice, marginalization, stigma
and illness.7,8 Leprosy has been shown to be associated with considerable reduction in the
quality of life compared to other dermatological conditions.8 Erythema nodosum leprosum
(ENL) is associated with worse HRQoL in individuals in Bangladesh and Brazil.9,10
ENL affects approximately 50% of individuals with lepromatous leprosy (LL) and 5–10% of
borderline lepromatous (BL) leprosy patients.11 ENL is characterized bymultiple tender, crops
of erythematous cutaneous nodules, with inflammation of nerves and other organs. Neuritis
during ENL episodes results in nerve function impairment. ENL is often chronic and may lead
to impaired organ function.11 ENL is often treated with prolonged courses of high-dose oral
corticosteroids which are associated with severe adverse effects and death.12 ENL is associated
with more hospital visits and hospital admissions than other leprosy patients.13
ENL characteristically affects patients in their thirties12 which has consequences on the
wider community as productivity is hampered and the family suffers. A previous study
conducted in Purulia by us showed that families with ENL are affected by both out of pocket
expenditure of treatment-seeking and loss of income household members.13 ENL therefore
exacerbates the financial situation of individuals who are already economically insecure. ENL
affects HRQoL in physical and psychological health domains.14
We aimed to measure HRQoL associated with ENL and compare it to individuals without
ENL.
Methods
A cross-sectional study was conducted of individuals attending the Purulia Leprosy Mission
Home and Hospital outpatient department between January and March 2015. The hospital is
located in district of Purulia in the state of West Bengal in Eastern India. Purulia district is
endemic for leprosy.15
Patients with leprosy including individuals newly diagnosed, those on MDT or those who
had completed MDT were eligible to participate. Participants were classified as having ENL,
Type 1 reaction (T1R), neuritis only and “no reaction or neuritis”.
Ethical approval was obtained from the ethics committee of The Leprosy Mission (TLM)
Trust India. Written informed consent was provided by all adult participants or the guardian
for those under the age of 18 years.
CASE DEFINITIONS
Leprosy was diagnosed in individuals who had hypopigmented, anaesthetic skin patches
and/or thickened nerves and/or acid-fast bacilli on slit skin smears.
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ENL was diagnosed if participants with BL leprosy or LL had crops of tender cutaneous or
subcutaneous lesions.
Type1Reaction (T1R) was defined as the development of erythema and oedema of pre-
existing leprosy skin lesions. There may be accompanying neuritis and oedema of the hands,
feet and face.
Neuritis was diagnosed if there was spontaneous nerve pain or tenderness; paraesthe-
sia; new sensory or motor nerve impairment.
The Bengali version of the SF-36 was administered to assess HRQoL.16 A lower score
reflects a worse HRQoL compared to a higher one. The SF-36 consists of 36 items and it
generates subscale scores for Physical Functioning (PH), Role Limitations due to Physical
problems (RP), Bodily Pain (BP), General Health perceptions (GH), Vitality (VT), Social
Functioning (SF), Role-limitations due to Emotional Problems (RE), and Emotional Well-
Being (MH). Two summary scores can also be derived from the SF-36: the Physical Component
Summary (Physical Health) and the Mental Component Summary (Mental Health) which
leads to an Overall Quality Score (HRQoL score).
The eight domains of SF-36 may be combined to derive physical health component
(PHC) and mental health component (MHC) scores. The PHC includes domains of physical
functioning (PF), role - physical (RP), bodily pain (BP) and general health (GH). The MHC
includes domains of vitality (VT), social functioning (SF), role-emotional (RE) and mental
health (MH).
Clinical and demographic data were collected using a standard form. A trained investigator
recruited participants and conducted the interview in a private setting. Literate patients who
were willing completed the questionnaire themselves.
Raw scale scores were summated and linearly transformed into a 0–100 scale assigned for
each sub-domain, domain and overall HRQoL. A score ranging from 0 (indicating the worse
health status) to 100 (indicating the best health status) and the higher scores indicating better
health.
The data were entered in to Microsoft Excel database and analyzed using SPSS statistics
programme. Simple frequencies and distribution measures were calculated for demographic
and disease profile and compared using Chi-square test. The differences between groups were
analyzed with independent ‘t’ test. The threshold for accepting statistical significance was p
<0.05.
Results
Two hundred and ninety individuals with a median age of 32 years (Range 14–82) were
recruited. Among the 290 participants, 44 (15.2%) had ENL, 39 (13.4%) T1R, 94 (32.4%)
neuritis and 113 (39.0%) had no reaction/neuritis. One hundred and sixty-six (57.2%) par-
ticipants were literate, of this 94 (32.4% in total patient) of them the questionnaire was self-
administered. Of the 290 participants, 184 were male and 106 (36.6%) were female (Table 1).
The median time since leprosy diagnosis for the ENL group was 10 months. Among ENL
patients, 9 (23.1%) had completedMDT, 14 (31.8%) patents with T1R and 39 (41.5%) patients
with neuritis had completed MDT. The disease profile was showed in Table 2.
RELIABILITY ANALYSIS
Internal consistency was assessed using Cronbach’s alpha coefficients and corrected item-scale
correlations. Corrected correlations between the items and their hypothesized scales ranged
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Table 1. Demographic profile of study participant (n =290)
No Reaction/
ENL T1 R Neuritis Neuritis Total X2
Variables n = 44 n = 39 n = 94 n = 113 n = 290 (P)
Gender
Male 28 (15%) 24 (13%) 61 (33%) 71 (39%) 184 (63%) 0.17
Female 16 (15%) 15 (14%) 33 (32%) 42 (40%) 106 (37%) (0.98)
Literate
Yes 29 (17%) 19 (11%) 49 (30%) 69 (42%) 166 (57%) 4.19
No 15 (12%) 20 (16%) 45 (36%) 44 (35%) 124 (43%) (0.24)
Mean age (years) 37.8 31.2 37.3 32.7 34.7
Occupation
Farmer 16 (16%) 14 (14%) 29 (29%) 42 (42%) 101 (35%) 8.37
House wife 14 (15%) 13 (14%) 33 (34%) 36 (38%) 96 (33%) (0.76)
Labor 6 (13%) 5 (11%) 16 (36%) 18 (40%) 45 (16%)
Student 4 (16%) 3 (12%) 5 (20%) 13 (52%) 25 (9%)
Business 4 (17%) 4 (17%) 11 (48%) 4 (17%) 23 (8%)
Note. Parenthesis indicates row percentages.
Table 2. Disease profile of study participant (n =290)
ENL T1 R Neuritis No R/Neuritis Total X2
Variables n = 44 n = 39 n = 94 n = 113 n = 290 (P)
Median time since leprosy diagnosis
In months 8 10 7.5 8 8
RJ Classification
TT 0 (0%) 0 (0%) 0 (0%) 3 (3%) 3 (1%)
BT 0 (0%) 26 (67%) 80 (85%) 85 (75%) 191 (66%) 134.29
BB 0 (0%) 1 (3%) 0 (0%) 0 (0%) 1 (0%) (0.000)
BL 25 (57%) 8 (21%) 4 (4%) 14 (12%) 51 (18%)
LL 19 (43%) 4 (10%) 7 (7%) 11 (10%) 41 (14%)
PNL 0 (0%) 0 (0%) 3 (3%) 0 (0%) 3 (1%)
MDT Status
Naïve 1 (2%) 8 (21%) 20 (21%) 34 (30%) 63 (22%) 22.14
Current 29 (66%) 22 (56%) 35 (37%) 47 (42%) 133 (46%) (0.001)
Completed 14 (32%) 9 (23%) 39 (41%) 32 (28%) 94 (32%)
WHO Disability grade
Grade 0 24 (55%) 16 (41%) 15 (16%) 101 (89%) 156 (54%) 117.21
Grade 1 6 (14%) 9 (23%) 19 (20%) 3 (3%) 37 (13%) (0.000)
Grade 2 14 (32%) 14 (36%) 60 (64%) 9 (8%) 97 (33%)
Relapse
Yes 1 (2%) 4 (10%) 0 (0%) 1 (1%) 6 (2%) 15.68
No 43 (98%) 35 (90%) 94 (100%) 112 (99%) 284 (98%) (0.001)
from 0.36 to 0.76 and were 0.4 or above for all items except for two items from the GH
scale. Cronbach’s alpha ranged from 0.924 (SF) to 0.937 (GH and MH) and exceeded the
0.70 standard for all scales.
Furthermore, in patients with leprosy reaction, ENL affected patients had lower mean scores
in all domains of SF-36 than the patients with T1R.
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Table 3. One-way ANOVA test between Disability Grade and domains of SF-36
Disability Mean Score
Grade n PF RP RE VT MH SF BP GH
Grade 0 156 80.9 74.5 75.2 78.9 81 82.9 72.8 55.7
Grade 1 37 80.1 60.1 58.6 76.2 76.4 75.3 63.2 50.8
Grade 2 97 65.2 41 39.5 71.1 73.7 62.5 52.8 49.1
p-value 0.000** 0.000** 0.000** 0.009* 0.007* 0.000** 0.000** 0.014*
Table 4. Independent ‘t’ test between No Reaction/neuritis vs ENL, T1R and Neuritis
Mean score ± Standard deviation
No reaction/ p-value
ENL T1R Neuritis neuritis No reaction/neuritis vs
Domain (n = 44) (n = 39) (n = 94) (n = 113) ENL T1R Neuritis
PF 73.07 ±23.482 76.41 ±27.790 71.60 ±23.557 79.47 ±25.906 0.156 0.534 0.024
RP 52.84 ±47.070 66.03 ±47.464 47.07 ±47.215 76.70 ±41.280 0.001 0.246 <0.001
RE 50.76 ±49.015 67.52 ±45.555 44.68 ±48.281 75.22 ±41.792 0.004 0.255 <0.001
VT 70.45 ±20.398 73.59 ±21.550 73.94 ±19.301 80.62 ±18.116 0.003 0.049 0.011
MH 71.27 ±19.525 78.67 ±16.061 75.91 ±19.250 82.09 ±16.588 0.001 0.265 0.014
SF 67.57 ±35.857 74.79 ±35.044 68.13 ±36.196 83.99 ±29.613 0.004 0.113 0.001
BP 59.77 ±35.372 69.74 ±36.457 55.38 ±38.082 73.14 ±32.708 0.026 0.588 <0.001
GH 49.66 ±15.863 55.15 ±19.129 48.26 ±18.269 57.09 ±17.249 0.014 0.558 <0.001
PHC 58.8 ±25.7 66.8 ±27.8 55.6 ±26.0 71.2 ±23.5 0.031 0.784 0.000
MHC 65.0 ±27.4 73.6 ±25.4 65.7 ±25.1 80.8 ±21.8 0.002 0.381 0.000
COMPARISON OF PARTICIPANT GENDER, OCCUPATION, RJ CLASSIFICATION AND DIS-
ABILITY GRADE WITH DOMAINS OF SF-36
There was no significant difference between gender, occupation and RJ classification in all the
domains of SF-36. For Disability Grade, there was a significant difference observed in all the
domains of SF-36 (Table 3).
COMPARISON OF PARTICIPANTS WITH ENL OR T1R OR NEURITIS AND PARTICIPANTS
WITH NO REACTION OR NEURITIS
The “no reaction or neuritis” group had higher scores in all domains of SF-36 than the ENL
group. There is a significant difference between the two groups in all domains except in PF
(Table 4).
The “no reaction or neuritis” group had higher scores in all domains of SF-36 than the
neuritis group. The differences were statistical significant in all domains (Table 4).
The “no reaction or neuritis” group had higher scores in all domains of SF-36 than T1R
group. However, there is a significant difference seen only in VT domain (Table 4).
PHYSICAL COMPONENT AND MENTAL COMPONENT
Individuals with ENL had significantly worse HRQoL than patients with “no reaction or
neuritis” in both the PHC and MHC. This was also the case for individuals with neuritis who
had significantly worse HRQoL compared with those without reaction or neuritis. There was
no significant difference found in HRQoL between individuals with T1R and those without
reaction or neuritis in both the PHC (Figure 1) and MHC (Figure 2).
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Figure 1. Physical Component Score for the study participants.
Figure 2.Mental Component Score for the study participants.
Discussion
This is the first study from India to examine HRQoL of individuals with ENL, T1R and those
with isolated neuritis. Studies from India, using the WHOQOL-bref questionnaire found that
leprosy affected people had lower QoL scores than the non-leprosy affected general population
especially in the physical and psychological domains.17
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Studies from Bangladesh and Brazil reported that ENL is associated with a severe impact on
HRQoL.9,10 In this study, a significant difference was found between individuals with ENL or
those with isolated neuritis and participants without reaction or neuritis. ENL affected patients
had lower HRQoL in all domains except in physical functioning than patients without reaction
or neuritis. In Bangladesh, Bowers et al.9 using the Bengali version of the SF-36 found that
patients with ENL had lower HRQoL in the domains than individuals without ENL.9 A similar
study by Sales et al.10 in Brazil found that people with ENL had impaired HRQoL compared
to those without ENL, however the difference was only significant in the bodily pain domain.10
Studies from Brazil using the WHOQOL-bref questionnaire showed that participants with
“leprosy reactions” tend to have more severe impairment in the physical domain.18 Lustosa
et al. measured HRQoL by SF-36, found that individuals with leprosy reactions in Brazil
had significantly lower HRQoL than those with no reaction.19 Participants with T1R had
a significant lower HRQoL score than those without reaction or neuritis, however this only
statistically significant in the VT domain. The impact of neuritis on HRQoL may be due to
NFI, neuropathic pain and disability and the contribution of such factors need to be further
clarified.20 In this study, patient with neuritis had a significant lower HRQoL score in all
domains than the patients without reaction/neuritis.
Our study has limitations. The study was cross-sectional and did not have matched controls.
The SF-36 is a general tool and may not reflect specific aspects of ENL and leprosy which may
have an important bearing on HRQoL.
In conclusion, this is the first study from India to show that ENL and neuritis is associated
with reduced HRQoL. Further prospective, adequately powered longitudinal studies should
be conducted which control for potential confounders including reactions with concomitant
neuritis. We suggest that HRQoL should be measured try and better understand the impact of
the disease on well-being, especially for patients with ENL and neuritis.
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